Trial reportJournal of the American Heart Association2025
Educational Attainment Level and Risk of Mortality and Cardiopulmonary Outcomes in High-Risk Patients With Cardiovascular Disease: The INVESTED Trial.
Trial report in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02787044 (INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEducational attainment level (EAL) is an indicator of socioeconomic status and has been shown to be inversely related with adverse health outcomes. However, the association between EAL and risk of clinical outcomes in high-risk patients with cardiovascular disease has not been extensively investigated.
methodsIn the INVESTED (Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure) trial, patients with recent heart failure or myocardial infarction hospitalization were randomized 1:1 to high-dose trivalent or standard-dose quadrivalent influenza vaccine from September 2016 to January 2019. We examined the association between EAL and risk of clinical outcomes for each participant across all enrolling seasons using adjusted Cox models stratified by trial entry season. Participants were categorized by EAL (≤high school, post-high school or trade, and ≥college).
resultsOf the 4912 participants (mean age: 65.5 years, 28% female, 80% White) with EAL information, 43% had high school, 29% had post-high school or trade, and 28% had ≥college as EAL. Those with higher EAL were more likely to be White or Asian, be married/with long-term partner, have higher left ventricular ejection fraction, have lower New York Heart Association class, and less likely to have comorbidities and risk factors than those with lower EAL. During follow-up (median: 9 months), 1706 (35%) participants experienced the composite of all-cause death or cardiopulmonary hospitalization. Compared with high school, higher EAL was associated with a stepwise decrease in risk (post-high school or trade: hazard ratio [HR], 0.88 [95% CI, 0.79-0.99]; ≥college: HR, 0.71 [95% CI, 0.63-0.81],
conclusionsHigh EAL is significantly associated with a decreased risk of adverse clinical outcomes in patients with high-risk cardiovascular disease after adjustment for other key risk factors, highlighting the need to consider EAL in risk assessment and target additional resources toward those with low EAL to improve prognosis. REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT02787044.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.